Financial Performance - The company's operating revenue for Q1 2025 was ¥40,624,818.43, a decrease of 70.21% compared to ¥111,835,236.68 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥8,028,308.26, representing a decline of 143.66% from a profit of ¥3,766,508.55 in the previous year[4] - The basic and diluted earnings per share were both -¥0.0293, down 143.73% from ¥0.0137 in the same period last year[5] - Net loss for Q1 2025 was ¥8,101,509.23, compared to a net profit of ¥21,423,835.82 in Q1 2024, indicating a significant decline in profitability[22] - Total operating revenue for Q1 2025 was ¥40,624,818.43, a decrease of 70.2% compared to ¥136,374,970.14 in Q1 2024[20] Research and Development - The total R&D investment amounted to ¥24,882,149.56, an increase of 50.68% compared to ¥16,512,853.64 in the previous year[5] - R&D investment accounted for 61.25% of operating revenue, an increase of 49.14 percentage points from 14.77% in the previous year[5] - Research and development expenses for Q1 2025 were ¥10,420,828.81, up 53.5% from ¥6,826,875.34 in Q1 2024, reflecting increased investment in innovation[20] Cash Flow and Liquidity - The net cash flow from operating activities was ¥99,338,104.85, an increase of 169.48% compared to ¥36,863,557.07 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was ¥99,338,104.85, an increase from ¥36,863,557.07 in Q1 2024[24] - Cash inflow from operating activities totaled ¥137,643,739.54 in Q1 2025, compared to ¥129,273,393.29 in Q1 2024, indicating improved cash generation[24] - The company's cash and cash equivalents increased to ¥550,365,903.94 from ¥490,270,275.37, representing an increase of approximately 12.0%[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,212,138,325.93, a decrease of 0.84% from ¥1,222,438,490.23 at the end of the previous year[5] - The equity attributable to shareholders was ¥928,563,813.61, down 0.86% from ¥936,592,121.87 at the end of the previous year[5] - Total liabilities as of the reporting date were ¥341,933,959.48, slightly down from ¥344,132,614.55 in the previous period[20] - The company’s total liabilities increased to ¥1,212,138,325.93, reflecting a stable financial position[16] Market Conditions - The decline in revenue and profit was primarily due to lower market demand for antiviral products and price reductions in response to market competition[8] - The company identified a need to adjust revenue recognition for certain products, resulting in a reduction of ¥24,539,700 in 2023 revenue and an increase in Q1 2024 revenue by the same amount[5] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,843[11] - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, accounting for 28.57% of total shares[12] - The number of shares held in the company's repurchase account is 1,570,586, accounting for 0.57% of the total share capital of 274,400,000 shares[12] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[13] Financial Reporting - The company did not apply new accounting standards starting from 2025[25] - The company’s financial reporting is overseen by Zhang Shixi, Li Liang, and Chen Xiaoning[26]

Financial Performance - The company's operating revenue for the third quarter was ¥35,783,445.19, a decrease of 25.93% compared to the same period last year, and a year-to-date decline of 55.32% to ¥251,110,585.69[3] - The net profit attributable to shareholders was -¥67,388,600.14 for the quarter, with a year-to-date loss of -¥57,215,916.93, representing an increase of 8,895.45% compared to the previous year[3] - Total operating revenue for the first three quarters of 2024 was CNY 251,110,585.69, a decrease of 55.32% compared to CNY 562,058,852.86 in the same period of 2023[18] - Net profit for the first three quarters of 2024 was a loss of CNY 65,925,432.36, compared to a profit of CNY 998,459.62 in the same period of 2023[20] - The basic and diluted earnings per share for the first three quarters of 2024 were both CNY -0.2089, compared to CNY 0.0024 in 2023[20] Research and Development - Research and development (R&D) expenses totaled ¥25,419,547.01 for the quarter, an increase of 49.13%, and accounted for 71.04% of operating revenue, up 35.75 percentage points[4] - The company is increasing its investment in R&D, particularly in the clinical trials for the Palivizumab inhalation solution project[8] - The company reported a significant increase in research and development expenses, totaling CNY 26,325,369.38 for the first three quarters of 2024, compared to CNY 63,925,857.68 in 2023[19] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥30,109,281.80, down 66.01% compared to the previous year[3] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 30,109,281.80, a decrease of 66.06% from CNY 88,584,510.48 in 2023[21] - The ending balance of cash and cash equivalents was $388,506,660.17, down from $561,729,383.46 at the beginning of the period[22] - The company reported a net decrease in cash and cash equivalents of -$173,222,723.29 during the period[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,069[10] - The largest shareholder, Hunan Pharmaceutical Development Investment Group Co., Ltd., holds 78,400,000 shares, representing 28.57% of total shares[10] Liabilities and Equity - The company's total liabilities amounted to CNY 158,904,683.58, while total equity was CNY 1,209,656,281.13 as of the reporting date[18] - The total equity attributable to shareholders of the parent company was CNY 1,236,281,830.33, a decrease from CNY 1,303,495,883.51 in the previous year[18] Cost Management - Total operating costs for the first three quarters of 2024 were CNY 221,340,831.77, down from CNY 508,120,982.75 in 2023, reflecting a reduction of 56.47%[19] - The company reported a significant reduction in sales expenses, which were CNY 64,474,681.29 for the first three quarters of 2024, down from CNY 341,793,551.23 in 2023[19] Asset Changes - The total assets at the end of the reporting period were ¥1,368,560,964.71, a decrease of 20.40% from the previous year-end[4] - Total current assets decreased from ¥1,271,857,772.05 as of December 31, 2023, to ¥911,150,884.10 as of September 30, 2024, a decline of approximately 28.37%[13] - Cash and cash equivalents decreased from ¥665,760,897.54 to ¥389,076,108.51, a reduction of about 41.5%[13] - Accounts receivable decreased from ¥520,668,671.48 to ¥427,921,860.87, a decline of approximately 17.8%[13] - Inventory increased from ¥30,365,696.49 to ¥67,051,501.23, an increase of about 120.8%[13] - Total current liabilities decreased from ¥428,035,296.07 to ¥153,760,240.79, a reduction of about 64.0%[14] - Short-term borrowings decreased significantly from ¥322,950,113.81 to ¥65,050,555.56, a decline of approximately 79.9%[14]

Financial Performance - The company achieved operating revenue of CNY 720.06 million in 2023, an increase of 3.04% compared to CNY 698.83 million in 2022[22]. - The net profit attributable to shareholders was a loss of CNY 10.87 million in 2023, improving from a loss of CNY 78.83 million in 2022[22]. - The net cash flow from operating activities was CNY 215.23 million, a significant recovery from a negative cash flow of CNY -160.09 million in 2022[22]. - The basic earnings per share for 2023 was -CNY 0.0396, an improvement from -CNY 0.2873 in 2022[23]. - The quarterly revenue for Q4 2023 was CNY 158.00 million, with a net profit loss of CNY -11.52 million, indicating fluctuations in performance throughout the year[26]. - Operating costs rose to 111.79 million yuan, reflecting a 12.55% increase year-on-year, resulting in a gross margin of 84.47%, down 1.31 percentage points[81]. - The company reported a net profit attributable to shareholders of -10.87 million yuan, with a net profit excluding non-recurring items of -3.54 million yuan[79]. - The revenue from antiviral drugs reached CNY 64,282.65 million, with a gross margin of 90.23%, reflecting a year-on-year revenue increase of 39.27%[111]. Research and Development - Research and development expenses accounted for 12.94% of operating revenue, up from 9.22% in the previous year, indicating increased investment in innovation[23]. - The company has 22 new products in development, including 7 innovative drug projects and 13 generic drug projects[33]. - The company has filed for 3 new invention patents and received 3 new authorized patents during the reporting period, totaling 35 authorized patents[33]. - The company has increased its R&D investment by 44.57% compared to the previous year, primarily due to increased clinical research costs for the drug Meifurenketone and improvements in the processes for Palivizumab Sodium Injection and Lactic Acid Ciprofloxacin Sodium Injection[57]. - The total R&D expenditure for the year is approximately ¥93.18 million, with a significant increase in capitalized R&D investment by 190.93% to ¥18.32 million[59]. - The company has developed core technologies in drug design and discovery, which are essential for new drug development[50]. - The company is conducting Phase II clinical trials for a new innovative drug targeting diabetic nephropathy, which is expected to be a significant breakthrough in treatment[33]. - The company is conducting Phase II clinical trials for a modified new drug, an inhalation solution of peramivir, which aims to be the world's first nebulized inhalation antiviral drug[45]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[8]. - The company has established a governance structure that includes a board of directors, supervisory board, and senior management, ensuring checks and balances[137]. - The board consists of 7 members, including 3 independent directors, ensuring a fair and transparent election process[138]. - The company has implemented a comprehensive internal control system to maintain effective oversight of its management team[141]. - The company adheres to strict information disclosure practices, ensuring transparency and equal access to information for all shareholders[141]. - The company held four shareholder meetings during the reporting period, all resolutions were approved without any rejections[146]. - The company has not reported any changes in shareholding for its directors and senior management during the reporting period[148]. - The company has maintained its internal control audit institution for 2023[146]. Market and Sales Strategy - The company is expanding its sales channels and adjusting its sales model to achieve steady revenue growth[34]. - The company has established a marketing network covering over 30 provinces, focusing on expanding the OTC market and enhancing brand awareness[36]. - The company is focusing on optimizing the evaluation and approval process for radioactive drugs, which are crucial for treating serious diseases[49]. - The company is actively planning new product launches to create new revenue and profit growth points[35]. - The company is focusing on expanding its product line in the antiviral and infectious disease treatment sectors, with a strong emphasis on innovative drugs[66]. - The company is accelerating the layout of its product lines in cardiovascular diseases, respiratory diseases, and antipyretic analgesics, with existing products including Benazepril Hydrochlorothiazide tablets and Atorvastatin Calcium tablets[68]. Risk Factors - The company emphasizes the importance of risk factors in its forward-looking statements, urging investors to be cautious[6]. - The company faces risks related to the lengthy and costly new drug approval process, with uncertainty regarding the success of its clinical trials and regulatory approvals for its pipeline products[73]. - The company’s core product, Palivizumab Sodium Injection, is at risk of being replicated by competitors, which could lead to increased market competition and potential price declines[75]. - The company faced risks related to centralized procurement policies that could significantly affect sales revenue and volumes of its main products[77]. Compliance and Regulatory Matters - The company received administrative regulatory measures from the China Securities Regulatory Commission on April 26, 2023, requiring corrections to prior accounting errors[168]. - The company disclosed corrected annual and quarterly reports for 2020 and 2021 on June 28, 2023, confirming the rectification of accounting errors[169]. - The company submitted a rectification report to the Shanghai Stock Exchange on July 5, 2023, in response to a regulatory warning received on June 6, 2023[170]. - The company has been actively addressing regulatory measures from the Hunan Securities Regulatory Bureau as part of its compliance efforts[173]. Employee and Management - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 4.8608 million RMB[164]. - The total remuneration for core technical personnel at the end of the reporting period amounted to 2.6229 million RMB[164]. - The company has a competitive compensation policy, providing various insurance and benefits to employees[187]. - The company employed a total of 360 staff, with 50 in the parent company and 310 in major subsidiaries[186]. - A total of 14 external training sessions and 344 internal training sessions were conducted in 2023 to enhance employee skills and teamwork[189].

Financial Performance - The company reported a profit distribution plan for 2024, proposing no cash dividends, no bonus shares, and no capital reserve conversion into shares [5]. - The company has not achieved profitability since its listing [3]. - The company reported a revenue of CNY 263.28 million for 2024, a decrease of 63.44% compared to the previous year [24]. - The net profit attributable to shareholders was a loss of CNY 356.90 million, significantly worsening from a profit of CNY 3.75 million in 2023 [24]. - Basic and diluted earnings per share for 2024 were both CNY -1.3007, reflecting a substantial decline from CNY 0.0137 in 2023 [22]. - The net cash flow from operating activities was CNY 1.39 million, a decline of 99.35% compared to the previous year [23]. - Total assets decreased by 28.90% to CNY 1.22 billion at the end of 2024, down from CNY 1.72 billion in 2023 [23]. - The weighted average return on equity was -31.87% for 2024, a significant drop from -0.83% in 2023 [22]. - The gross margin decreased to 54.59%, down 29.89 percentage points year-on-year [86]. - The total profit for the period was -388.64 million yuan, with a net profit attributable to shareholders of -356.90 million yuan [70]. Research and Development - The company’s R&D expenditure accounted for 43.81% of its revenue, an increase of 30.87 percentage points year-on-year [22]. - The company’s R&D investment totaled 115.34 million RMB, accounting for 43.81% of operating revenue, an increase of 30.87 percentage points from the previous year [37]. - The total R&D investment for the year reached ¥115,337,991.94, an increase of 23.77% compared to the previous year [56]. - The company has cumulatively obtained 23 authorized patents and 4 software copyrights as of December 31, 2024 [37]. - The company is focusing on continuous cost reduction and efficiency improvement while streamlining its organizational structure [37]. - The company is conducting Phase II clinical trials for the acid-suppressing drug, with smooth participant enrollment, aiming to delay kidney fibrosis and improve kidney function in diabetic nephropathy treatment [39]. - The company has established a research and development system combining innovative and generic drugs, with a product lineup of 38 chemical drug varieties and 58 formulation production approvals [49]. - The company has launched the first domestic anti-influenza innovative drug, Palivizumab Sodium Injection, and is conducting Phase III clinical trials for a modified new drug, Palivizumab Inhalation Solution [50]. - The company has successfully developed products like Acetaminophen Mannitol Injection using its soft bag infusion technology, which offers advantages over traditional glass bottle infusions [54]. - The company is actively pursuing a diversified approach to international market expansion, including independent clinical development and licensing out [52]. Market and Competition - The company adjusted its sales strategy and reduced prices for core products due to increased market competition and policy changes [24]. - The company experienced a significant decline in sales due to fewer flu cases in the second, third, and fourth quarters of 2024 [24]. - The company is responding to increased market competition and price pressures due to policy changes and intensified market competition in the pharmaceutical sector [35]. - The company is preparing to submit applications for several generic drugs, including Acetaminophen Mannitol injection [115]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential deals [153]. Governance and Compliance - The audit report issued by Da Hua Certified Public Accountants is a standard unqualified opinion [4]. - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report [3]. - The company has not violated decision-making procedures for external guarantees [7]. - The company has not disclosed any special governance arrangements [8]. - The company has not faced any issues regarding independence from its controlling shareholders [143]. - The company has established a comprehensive internal control system to ensure compliance and enhance operational efficiency [185]. - The company has implemented a strict information disclosure management system to ensure transparency and fairness in communications with investors [142]. - The company has not reported any violations of laws or regulations by its directors or senior management [142]. Environmental and Social Responsibility - The company emphasizes ESG principles in its operations, focusing on climate change, resource management, and social responsibility [188]. - The company invested ¥1,447,300 in environmental protection during the reporting period [191]. - The company has established an environmental protection mechanism and has not experienced any environmental pollution incidents or administrative penalties [192]. - The company has a comprehensive wastewater treatment facility with a processing capacity of 600 tons per day, operational since March 2017 [197]. - The company is committed to reducing pollutant emissions and enhancing energy efficiency through clean production practices [189]. Employee and Management - The company has a total of 366 employees, with 247 in production, 33 in sales, 42 in technology, 10 in finance, and 34 in administration [173]. - The total compensation for key personnel during the reporting period amounted to 519.61 million yuan [147]. - The company has maintained a consistent shareholding structure with no changes in the number of shares held by key personnel throughout the year [147]. - The company is focused on ensuring a smooth transition as key personnel retire and new members are integrated into the team [148]. - The company is committed to adhering to legal retirement age regulations for its employees [148].

湖南南新制药股份有限公司（以下简称"公司"）第二届监事会第十三次会 议于 2025 年 4 月 28 日在广州南新制药有限公司 313 会议室以现场与通讯相结合 的方式召开。 本次会议通知于 2025 年 4 月 21 日以邮件方式向全体监事发出，本次会议应 出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开程序均符合《公司法》 《证券法》等法律法规和规范性文件以及《公司章程》的规定。 二、监事会会议审议情况 本次会议由公司监事会主席张平丽女士主持。经与会监事认真审议，以记名 投票方式，通过了如下议案： 证券代码：688189 证券简称：南新制药 公告编号：2025-006 湖南南新制药股份有限公司 第二届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 （一）审议通过《关于<2024 年度监事会工作报告>的议案》 2024 年度，公司监事会严格遵守《公司法》《证券法》以及《公司章程》的 有关规定，以维护公司利益、股东权益为原则，勤勉履行法律和股东所赋予的职 责和 ...

一、本次交易概述 湖南南新制药股份有限公司（以下简称"公司"）于 2024 年 11 月 15 日召开 了第二届董事会第十三次会议和第二届监事会第十一次会议，2024 年 12 月 2 日 召开 2024 年第一次临时股东大会，审议通过了《关于拟公开挂牌转让全资子公 司 100%股权的议案》和《关于转让全资子公司股权暨被动形成财务资助的议案》， 同意在湖南省联合产权交易所有限公司公开挂牌转让公司的全资子公司常德臻 诚医药科技有限公司 100%股权，具体内容详见公司于 2024 年 11 月 16 日披露的 《关于拟公开挂牌转让全资子公司 100%股权暨被动形成财务资助的公告》（公告 编号：2024-047）。 二、本次交易终止的情况 证券代码：688189 证券简称：南新制药 公告编号：2025-004 特此公告。 湖南南新制药股份有限公司 关于终止挂牌转让全资子公司 100%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次交易挂牌期满后，公司对市场情况进行再次调研论证，经审慎研究，公 司决定终止本次挂牌转 ...

Financial Performance - Total revenue for 2024 was CNY 27,398.33 million, a decrease of 63.20% compared to the previous year[4] - Operating profit for 2024 was CNY -39,189.22 million, a decline of 5,387.12% year-over-year[4] - Net profit attributable to shareholders of the parent company was CNY -35,423.77 million, down 9,542.56% from the previous year[4] - Basic earnings per share for 2024 were CNY -1.2910, a decrease of 9,523.36% compared to the previous year[4] - The weighted average return on net assets was -31.18%, a decrease of 31.47 percentage points compared to the previous year[4] Assets and Equity - Total assets at the end of 2024 were CNY 123,373.35 million, a reduction of 29.00% from the previous year[6] - Shareholders' equity attributable to the parent company was CNY 95,387.82 million, down 27.63% year-over-year[6] Strategic Adjustments - The company adjusted sales strategies and reduced prices for core products due to industry policy changes and increased market competition[7] - The company implemented cost reduction measures, resulting in a significant decrease in selling, administrative, and financial expenses compared to the previous year[7] Report Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[9]

Financial Performance Forecast - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -260 million and -360 million yuan[4]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -262 million and -362 million yuan for 2024[4]. - In 2023, the total profit was 7.6073 million yuan, with a net profit attributable to shareholders of the parent company of 3.7515 million yuan[5]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was 11.0774 million yuan in 2023[5]. Market and Operational Challenges - The company has adjusted and optimized sales strategies due to industry policy environment and intensified market competition, leading to a decrease in sales prices for core products[6]. - The company has experienced a decline in operating income and gross margin due to fewer flu cases in the second, third, and fourth quarters of 2024[6]. Cost Management and Strategic Adjustments - The company has implemented cost reduction and efficiency improvement measures, resulting in a significant decrease in selling, administrative, and financial expenses compared to the previous year[7]. - The company plans to further adjust marketing strategies and enhance cost control to strengthen core competitiveness and respond to industry changes[7]. Earnings Forecast Reliability - There are no significant uncertainties affecting the accuracy of this earnings forecast[8]. - The preliminary financial data may differ from the final figures disclosed in the 2024 annual report[9].

北京大成（广州）律师事务所 关于湖南南新制药股份有限公司 2024 年第二次临时股东大会的 法律意见书 guangzhou.dachenglaw.com 广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 14 层、15 层（510623） 14/F,15/F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China Tel:+8620-85277000 Fax:+8620-85277002 关于湖南南新制药股份有限公司 2024 年第二次临时股东大会的法律意见书 致：湖南南新制药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东大会规则（2022 年修订）》（以下简称"《股东大会规则》"）等法律、法规 和其他有关规范性文件的要求，北京大成（广州）律师事务所（以下简称"本所"） 接受湖南南新制药股份有限公司（以下简称"公司"）的委托，指派律师参加公司 2024 年第二次临时股东大会（以下 ...

证券代码：688189 证券简称：南新制药 公告编号：2024-058 湖南南新制药股份有限公司 2024 年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 12 月 27 日 （二） 股东大会召开的地点：广东省广州市黄埔区开源大道 196 号广州南新制 药有限公司 313 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 本次股东大会由湖南南新制药股份有限公司（以下简称"公司"）董事会召 集，由董事长胡新保先生主持，会议采用现场投票与网络投票相结合的表决方式 进行表决。本次会议的召集、召开程序与表决方法、表决程序符合《公司法》《公 司章程》及《上海证券交易所科创板股票上市规则》等法律、法规和规范性文件 的规定。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事 7 人，出席 7 人； 2、 公司在任监事 3 人， ...